MRKR - Marker Therapeutics gets new chief medical officer

2023-05-08 08:49:36 ET

• Clinical-stage immuno-oncology company, Marker Therapeutics ( NASDAQ: MRKR ) appoints of Monic Stuart, M.D., as its new Chief Medical Officer.
• Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601.
• Dr. Stuart joins Marker Therapeutics as a consultant after having most recently worked as interim Chief Medical Officer, Head of Clinical Development or Clinical Advisor for numerous biotechnology and pharmaceutical companies worldwide.

For further details see: